270MO An international update of the EORTC questionnaire for assessing quality of life in breast cancer patients: Results of the validation study phase IV EORTC QLQ-BR42

• DOI: 10.1016/j.esmoop.2024.103329
• Publication Date: 2024-05-17T11:21:29Z
• Authors: V. Bjelic-Radisic; F. Cardoso; J. Weis; G. Velikova; D.A. Cameron; E.G.C. Brain; R.A. Da Costa Vieira; E.C. Inwald; M. Pinto; K. Pogoda; J. Arraras; E. Bleiker; N. Hoefnagels; C-C. Huang; O. Shamieh; Y.B. Belay; E. Greimel; A. Bottomley; M. Sprangers; N. Aaronson

The EORTC QLQ-BR23, developed in 1996, was one of the first disease-specific questionnaires, to assess quality life (QoL) patients with breast cancer (BC). However, since major changes BC treatment have occurred, requiring updating module. results phase I-III were presented at ESMO Meeting 2018. This abstract presents final IV validation study updated version, QLQ-BR42. update QLQ-BR23 module followed standard guidelines.Developmental I-II, a systematic literature review by interviews and health care providers, resulted 15 QoL issues transformed into 27 items relevant for patients. preliminary pre-tested III toassess their perceived importance acceptability. Phase designed psychometric properties questionnaire an international field study. Data all usedfor analyses, i.e., evaluation scale structure, internal consistency, test-retest reliability, convergent, discriminant, clinical validity, responsiveness change. registered on clinicaltrials.gov database (NCT04270123). Between May 2019 September 2021, 576 from 17 countries (16 different languages) enrolled analyses containing 42 divided ten scales: Breast Symptoms, Body Image, Sexual Functioning, Arm Systemic Chemotherapy Side Effects, Skin Toxicity/Neuropathy, Musculo/Skeletal Endocrine-related Satisfaction, Vaginal 3 single items: Weight Gain, Enjoyment Future Perspective. QLQ BR42 is revised innovative that incorporates original BR23 remain relevant, combined 19 new address side effects therapies over past 20 years. comprehensive well suited future trials.